![Chris Stevens](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Chris Stevens
Nessuna posizione attualmente
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Christopher Morabito | M | 54 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Alexey L. Margolin | M | 71 |
Alnara Pharmaceuticals, Inc.
![]() Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | 2 anni |
Chip Clark | M | 56 |
Arsanis, Inc.
![]() Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | 2 anni |
David McGirr | M | 69 |
Arsanis, Inc.
![]() Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | - |
Ashley L. Dombkowski | M | - |
Alnara Pharmaceuticals, Inc.
![]() Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
Lee R. Brettman | M | 77 |
Alnara Pharmaceuticals, Inc.
![]() Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
Robert Gallotto | M | 59 |
Alnara Pharmaceuticals, Inc.
![]() Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
Thomas Rowland | M | 58 |
Alnara Pharmaceuticals, Inc.
![]() Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | - |
Hugh Wight | M | - |
Alnara Pharmaceuticals, Inc.
![]() Alnara Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA. | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 9 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Chris Stevens
- Contatti personali